Loading...
•
Jun 30, 2023
Verve Therapeutics Q2 2023 Earnings Report
Verve Therapeutics reported financial results for the second quarter of 2023 and highlighted company progress.
Key Takeaways
Verve Therapeutics reported a net loss of $54.0 million for the second quarter of 2023. The company's cash position remains strong with $462.5 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2026. The company is advancing its pipeline, including VERVE-101, VERVE-102, and VERVE-201, and progressing in its collaboration with Lilly.
Initial clinical data from the heart-1 Phase 1b clinical trial of VERVE-101 is expected in the fourth quarter of 2023.
Preclinical studies and clinical operations activities are underway to support the initiation of clinical trials for VERVE-102 and VERVE-201 in 2024.
The Lp(a) program is advancing in collaboration with Lilly, with Verve receiving $60 million in combined upfront payment and equity investment in August 2023.
Verve Therapeutics is well-capitalized with a cash runway into 2026.
Revenue by Segment
Forward Guidance
Verve Therapeutics expects to report initial clinical data from the heart-1 Phase 1b clinical trial of VERVE-101 in the fourth quarter of 2023 and initiate clinical trials for VERVE-102 and VERVE-201 in 2024. The company's existing cash, cash equivalents, and marketable securities, including the additional $60.0 million upfront payment and equity investment from Lilly in August 2023, are expected to be sufficient to fund its operations into 2026.
Positive Outlook
- Initial clinical data from heart-1 trial expected in Q4 2023
- Clinical trials for VERVE-102 on track for first half of 2024
- Clinical trials for VERVE-201 on track for second half of 2024
- Lp(a) program advancing with Lilly collaboration
- Cash runway extends into 2026
Challenges Ahead
- Ongoing clinical trial enrollment outside the United States due to FDA hold
- Reliance on regulatory clearance for clinical trial initiations
- Dependence on Lilly for funding Lp(a) program through Phase 1
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...